

Cashiering and Board Use Only			
Receipt #	Payor ID	Beneficiary ID	Amount
1-3204	6019072	437704	50.00



**STATE BOARD OF OPTOMETRY**  
 2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834  
 P (916) 575-7170 F (916) 575-7292 www.optometry .ca.gov



Continuing Education Course  
 Approval Checklist

Title:

Provider Name:

- Completed Application
  - Open to all Optometrists?  Yes  No
  - Maintain Record Agreement?  Yes  No
- Correct Application Fee
- Detailed Course Summary
- Detailed Course Outline
- PowerPoint and/or other Presentation Materials
- Advertising (optional)
- CV for EACH Course Instructor
- License Verification for Each Course Instructor
  - Disciplinary History?  Yes  No



**STATE BOARD OF OPTOMETRY**  
 2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834  
 P (916) 575-7170 F (916) 575-7292 [www.optometry.ca.gov](http://www.optometry.ca.gov)



**CONTINUING EDUCATION COURSE APPROVAL  
 APPLICATION**

**\$50 Mandatory Fee**

Pursuant to California Code of Regulations (CCR) § 1536, the Board will approve continuing education (CE) courses after receiving the applicable fee, the requested information below and it has been determined that the course meets criteria specified in CCR § 1536(g).

In addition to the information requested below, please attach a copy of the course schedule, a detailed course outline and presentation materials (e.g., PowerPoint presentation). Applications must be submitted 45 days prior to the course presentation date.

**Please type or print clearly.**

<b>Course Title</b> Suprachoroidal Space	<b>Course Presentation Date</b> 04 / 08 / 2017
---	---

**Course Provider Contact Information**

<b>Provider Name</b> Amy Atondo (First) (Last) (Middle)		
<b>Provider Mailing Address</b> Street 1450 San Pablo St. City Los Angeles, State CA Zip 90033		
Provider Email Address amy.atondo@med.usc.edu		
Will the proposed course be open to all California licensed optometrists?	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO	
Do you agree to maintain and furnish to the Board and/or attending licensee such records of course content and attendance as the Board requires, for a period of at least three years from the date of course presentation?	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO	

**Course Instructor Information**

Please provide the information below and attach the curriculum vitae for each instructor or lecturer involved in the course. If there are more instructors in the course, please provide the requested information on a separate sheet of paper.

<b>Instructor Name</b> Alena Reznik (First) (Last) (Middle)		
License Number A113775	License Type MD	
Phone Number (323) 442-6372	Email Address Alena.reznik@med.usc.edu	


*I declare under penalty of perjury under the laws of the State of California that all the information submitted on this form and on any accompanying attachments submitted is true and correct.*

Signature of Course Provider

3/6/2017  
 Date

# USC Roski Eye Institute

Keck Medicine of USC



Dear Colleague:

Please join us for our FREE 3 HOUR Glaucoma CE by Drs. Sahar Bedrood, MD, PhD, Alena Reznik, MD and Grace Richter, MD, MPH on April 8, 2017. We invite you to participate in this specialty 3 hour continuing education (CE) lecture. We will have a Q & A after each Lecture. Lectures include:

08:00am – 08:30am	Registration and Continental Breakfast
08:30am – 08:40am	Welcome and Introduction by Dr. Alena Reznik
08:40am – 09:40am	OCT in Glaucoma by Dr. Grace Richter
09:40am – 10:40am	Biomechanical Glaucoma Damage By Dr. Sahar Bedrood
10:40am – 10:55am	Break
10:55am – 11:55am	Suprachoroidal Space by Dr. Alena Reznik

**USC Roski Eye Institute**  
**1450 San Pablo St. 3<sup>rd</sup> Floor Conference Room**  
**Los Angeles, CA 90033**

**Free registration** is provided for your convenience.

**RSVP acceptance or regrets to Amy Atondo at [amy.atondo@med.usc.edu](mailto:amy.atondo@med.usc.edu)** Should you have any questions or require additional information, please call 323-442-6372.

The Keck School of Medicine of the University of Southern California designates this lecture for a maximum of 3 CE credits. Registrar and Administrator for the Optometry Portion is California State Board of Optometry.



Grace Richter, MD, MPH



Sahar Bedrood, MD, PhD



Alena Reznik, MD

Department of Ophthalmology \* USC Eye Institute  
Keck School of Medicine \* University of Southern California

# Optometric Course Outline

Suprachoroidal Space: Friend or a Foe (Overview of MIGS and MEGS). 4/08/2017.

## **Sponsoring Organization**

USC Roski Eye Institute Keck School of Medicine USC, Los Angeles, CA

## **Course Faculty**

Alena Reznik MD, Assistant Professor of Ophthalmology

## **Program Overview**

This course is designed to educate optometrists on the treatment algorithm for glaucoma including minimally invasive glaucoma surgery and follow-up care. Emphasis will be on medications, laser trabeculoplasty and minimally invasive glaucoma surgery such as microstents.

## **Target Audience**

This course is designed for practicing optometrists

## **Educational Objectives**

Upon completion of this course optometrists should be able to:


- Describe the rationale and principles underlying treatment of glaucoma
- Identify patients who would benefit the most from the treatment
- Discuss the published clinical results regarding the efficacy and safety of the current glaucoma treatment/surgery

## **Course Outline**

- I. Overview of glaucoma definition
  - a. Description
    - i. Early vs moderate vs advanced
  - b. History
- II. Detection
  - a. HVF
  - b. OCT
  - c. OCT angio
- III. Treatment
  - a. Medications
  - b. Laser
  - c. Minimally invasive glaucoma surgery
  - d. Incisional glaucoma surgery
- IV. Clinical Results for each of treatment modality
  - a. Efficacy
  - b. Safety
  - c. Complications
  - d. Limitations


## Suprachoroidal Space: Friend or a Foe (Overview of MIGS and MEGS)

Alena Reznik MD  
 Assistant Professor of Ophthalmology  
 Glaucoma Service  
 Cell 310-980-6038  
 alenarez@med.usc.edu



## Financial Disclosure


- Alcon (speaker)





## Who we are

- Glaucoma service- 6 glaucoma surgeons
- Beverly Hills (Wilshire/Doheny)
- Pasadena (Fair Oaks)
- Arcadia
- Downtown LA (Keck)

Emergency referral line : 323-442-EYES



## Treatment Pyramid

## Meds

- Allergies- Preservative-free compounds
- Cost
- Quality of life
- Compliance; lack of adherence-> vision loss
- Less than 50% of patients are still using drops after one year<sup>1</sup>
- Up to 60% of glaucoma patients cannot use drops properly<sup>2</sup>




<sup>1</sup> Nordstrom et al, Am J Ophthalmol 2005; 140:598  
<sup>2</sup> Newman-Casey et al, Ophthalmology 2015; 122:1308



## Drug Burden: Multiple Medications in Medicare Population

Based on 1996 MCBS Cost and Use Data Files  
 (Over 65 population of 27,285,989)



Number of Medications	Percentage
1 Medication	13%
2 Medications	15%
3 Medications	14%
4 Medications	12%
5 Medications	10%
6 Medications	7%
7 Medications	5%
8 Medications	3%
9 or more Medications	2%
No Medications	12%

- 58.3% of the > 65 years old population is on 3 or more medications. Studies have shown that the more medication taken the worse the patient compliance.




### Complications of trab/tubes

- Hypotony
- Failure
- Blebitis/ endophthalmitis
- Suprachoroidal heme
- RD




### Changing Approach to Surgery

- Micro- INCISIONAL Glaucoma Surgery
- Preserve the conj! Ab-interno approach
- Intervene early in disease, reduce burden
- Safety
- Stepwise surgical approach
- Less recovery time, less manipulation
- Modest efficacy



### 3 MIGS Targets



### MIGS target


Schlemm's	Suprachoroidal	Subconjunctival
• Extremely high safety	• Large potential space	• Gold standard
• Combo phaco	• Combo phaco	• Combo Phaco
• EVP floor	• Variability	• Healing dependent
• Technical skill level	• dependent on healing	• dependent
• IOP results modest	• IOP results modest	• IOP results excellent



FDA approved:



FDA Approval pending:




### Schlemm's Canal Procedures

- TM Microstenting- iStent, iStent inject
- TM Scaffolding
- TM Cutting
- TM Ablation



### iStent-bypass


- 1mm length, 0.33 mm height
- Micro bypass
- Smallest implant: 60 micrograms
- Titanium; MRI safe




**USC Roski Eye Institute** **Children's Hospital of Orange County**

### iStent-bypass

- Disposable
- Re-acquisition
- Sterile
- Pre-loaded



**USC Roski Eye Institute** **Children's Hospital of Orange County**



### iStent Pivotal US IDE Trial

*Prospective, randomized, multi-centered study of POAG patients who underwent iStent + cataract surgery vs. cataract surgery (CE) alone.*

**290 eyes of 289 subjects at 29 sites**

- 240 eyes of 239 randomized subjects with cataract and mild-to-moderate OAG (1:1 randomization)
- 50 additional non-randomized subjects for safety

**Patient population**

- Mild-to-moderate POAG
- IOP  $\leq$  24 mm Hg on 1-3 medications
- Post-medication washout IOP 22 – 36 mm Hg



**Efficacy endpoints**

- Primary: IOP  $\leq$  21 mm Hg without medications at month 12
- Secondary: IOP reduction  $\geq$  20% without medications at month 12

**Follow-up through 2 years postoperative**

Samuelson DJ, Katz F, Wells MA, et al. Randomized evaluation of the Trabectome micro bypass system. JAMA. 2012;307:1914-22.



**USC Roski Eye Institute** **Children's Hospital of Orange County**





### Reported Adverse Events


Excerpts from complete listing of safety population	iStent + cataract surgery N=116 n(%)	Cataract surgery only N=117 n(%)
Early postoperative corneal edema	9 (8%)	11 (9%)
Any BCVA loss of at least one line at or after the 3 month visit	8 (7%)	12 (10%)
Posterior capsular opacification	7 (6%)	12 (10%)
Stent obstruction	5 (4%)	NA
Blurry vision or visual disturbance	4 (3%)	8 (7%)
Elevated IOP	4 (3%)	5 (4%)

**Comparable safety profile to cataract surgery**



- ### Schlemm's Canal Procedures
- TM Microstenting
  - TM Scaffolding- Hydrus
  - TM Cutting
  - TM Ablation
- 






- ### Ongoing Hydrus RCTs
- 1000+ pts (US & Europe)
  - Hydrus+Phaco vs Phaco
  - Hydrus vs iStent
  - Hydrus vs 2 iStents

- ### New Schlemm's Canal Procedures
- TM Microstenting
  - TM Scaffolding
  - TM Cutting- Goniotomy (CHLA), GATT (Texas), Kahook Dual Blade
  - TM Ablation- Trabectome

- ### Trabectome
- Handpiece-disposable, one use
  - Bipolar electro-surgical pulse with I/A
  - Irrigation: maintains AC
  - Aspiration: removes ablated tissue
  - Electrosurgical pulse: ablates TM and unroofs Schlemm's canal
- 





- ### Trabectome
- Mosaed et al
  - 4659 cases, 90 months f/up
  - Success: IOP<21, or 20% reduction
  - Pre-op IOP: 23.1, Post-op: 17.2
  - Meds: pre-op 2.6, post-op 1.1
  - Hyphema, failure.

### Suprachoroidal Procedures


- Cypass (FDA approved)
- iStent Supra (non-FDA approved)




### CyPass (Alcon) (FDA approved 8/2016)

### CyPass (Alcon) (FDA approved 8/2016)




### CyPass (Alcon) (FDA approved 8/2016)




### CyPass (Alcon) COMPASS

- 505 pts; US
- CyPass+ Phaco (374) vs Phaco alone (131)
- 2 year f/up
- Open angle glaucoma only
- 73% of the CyPass+Phaco and 58% Phaco achieved 20% reduction in unmedicated IOP at 24 months
- Transient hypotony (3%)



### Subconj space

- Xen gel stent- FDA approved 11/22/16 (45 micron size)
- Bleb is a bleb- manage it, addition of MMC (subconjunctival injection)



### Allergan Xen Gel Stent

- 6 mm hydrophilic tube made of porcine gelatin cross-linked with glutaraldehyde.
- not degraded/ not rejected
- soft upon hydration







### Allergan Xen Gel Stent


- Final IOP control depends on the lumen size (larger lumen will produce a larger IOP decrease). 45 vs 63 vs 140


$$\Phi = \frac{dV}{dt} = v\pi R^2 = \frac{\pi R^4}{8\eta} \left( \frac{-\Delta P}{\Delta x} \right) = \frac{\pi R^4 [\Delta P]}{8\eta L}$$

- The implantation is identical for all











### Allergan Xen Gel Stent






### Allergan Xen Gel Stent

- N=975 (45/63/140 micron lumen size)
- Pre-op: IOP 22.9 mmHg on 2.8 medications (no medication wash out).
- Post-op: IOP at 12 months was 15.6 mmHg on 1 medication.
- IOP at 36 months 13.2 and less than 0.7 medication was used.
- Postoperative medication use was reduced by 82%.
- Less than 3 % chance of hypotony, shallow AC/choroidal effusion
- No cases of endophthalmitis, flat AC or suprachoroidal heme





### Current Pt Profile

**MIGS**

- Mild/moderate disease
- Open angle
- Modest IOP target
- ~ 15-16 mmHg
- Able to tolerate some meds if needed

**Trab**

- Advanced disease
- Open or closed angle
- Low IOP target <12 mmHg
- Intolerant to meds

**Tube (AGV vs BGI) surgery**

- No conj/previous surgery

### Treatment Pyramid

### Thank you!

- Dr. Rohit Varma
- Dr. Ike Ahmed
- Dr. Sahar Bedrood
- Dr. Grace Richter

- Cell 310-980-6038
- [alenarez@med.usc.edu](mailto:alenarez@med.usc.edu)
- Emergency referral line : 323-442-EYES

### Glaucoma Treatment Algorithm

*Now & Potentially in 5 years*

### Concomitant Cataract & Glaucoma Patients - US

**Significant Treatment Opportunity**  
One in five Cataracts Eyes on OHT Medication

20.5%  
Cataract +  
Minimum of 1  
OHT Med

3.5M US Cataract Procedures

## Ongoing Hydrus RCTs

Hydrus + Phaco vs Phaco in Mild to Moderate POAG	
<p><b>HYDRUS II</b>                      Principal Investigator: Norbert Pfeiffer                      Medical Monitor: Tom Samuelson, MD                      7 centers, 4 countries (non-US), N=100                      Published Ophthalmology 2015</p>	<p><b>HYDRUS IV — US IDE</b>                      Principal Investigator: Alan Crandall, MD                      Medical Monitor: Kuldev Singh, MD                      30 Centers (8 non-US), N=555                      Enrollment completed</p>
Comparative Effectiveness Studies	
<p><b>HYDRUS III – Hydrus v iStent</b>                      Mild to moderate POAG &amp; Cataract                      Principal Investigator: Ika Ahmed                      Medical Monitor: Keith Barton                      9 Centers, 7 countries (non-US), N=220</p>	<p><b>HYDRUS v: Hydrus v z iStents</b>                      Moderate POAG in phakopseudo eyes                      Principal Investigator: Julian Fejoo                      Medical Monitor: Ika Ahmed                      6 centers, 6 countries (non-US), N=120</p>






# CURRICULUM VITAE

ALENA REZNIK, MD

SEPTEMBER 19, 2016

## PERSONAL INFORMATION:

### **Work**

USC Eye Institute  
1450 San Pablo Street 4806  
Los Angeles, CA 90033

### **Home**

8568 Burton Way  
Apt 102  
Los Angeles, CA 90048

Phone: 323-4426383  
Fax: 323-4426412

Citizenship: US  
Email: alena.reznik@med.usc.edu

## EDUCATION AND PROFESSIONAL APPOINTMENTS

### **EDUCATION:**

2005 *BS, Summa Cum Laude, Microbiology/Immunology/Molecular Genetics, UCLA, LA*  
2009 *MD, Johns Hopkins University School Of Medicine, Baltimore*

### **POST-GRADUATE TRAINING:**

2009-2010 *Internship in Internal Medicine, UC Davis Medical Center, Sacramento*

2010-2013 *Ophthalmology Residency, UC Davis Medical Center, Sacramento*

2013-2014 *Glaucoma Fellowship, Jules Stein Eye Institute, UCLA, LA*

### **HONORS, AWARDS:**

2017	<i>Rising Star 2017</i>	<i>Top Doctors</i>
2016	<i>Top Doctor 2016</i>	<i>Pasadena Magazine</i>
2016	<i>Rising Star 2016</i>	<i>Top Doctors</i>
2012	<i>ARVO Travel Grant</i>	<i>ARVO, Ft.Lauderdale, FL</i>
2007	<i>AFAR Research Fellow</i>	<i>Johns Hopkins Hospital, Baltimore, MD</i>
2008-2009	<i>The Roothbert Fund Fellow</i>	<i>Johns Hopkins Hospital, Baltimore, MD</i>
2008-2009	<i>Marilyn and Marshall Butler Scholarship</i>	<i>Johns Hopkins Hospital, Baltimore, MD</i>
2007-2008	<i>William W. More, Ph.D. Memorial Scholarship</i>	<i>Johns Hopkins Hospital, Baltimore, MD</i>
2007-2009	<i>HIAS Scholarship</i>	<i>NY</i>
2007-2009	<i>Ruth G White PEO Scholarship</i>	<i>Johns Hopkins Hospital, Baltimore, MD</i>
2007-2009	<i>Ethel O. Gardner PEOP Scholarship</i>	<i>Johns Hopkins Hospital, Baltimore, MD</i>
2007	<i>Travel Grant AGS</i>	<i>WA</i>

**ACADEMIC APPOINTMENTS:**

2014-current	Assistant Professor of Ophthalmology	USC Eye Institute, USC, LA, CA
--------------	--------------------------------------	--------------------------------

**TEACHING****DIDACTIC TEACHING:***Institution USC*

2014	Femtosecond Laser in Glaucoma Surgery	1Hr	Lecturer
2015	Novel Techniques in Glaucoma Surgery	2Hrs	Lecturer
2015	New Treatments in Advanced Glaucoma	2Hrs	Lecturer
2015	Glaucoma Curriculum (USC LAC Residency)	12Hrs	Lecturer
10/2015	Wet Lab "Minimally Invasive Glaucoma Surgery/Trabectome"	3Hrs	Lecturer
11/2015	Wet Lab "iStent and Angle Surgery"	3Hrs	Lecturer
11/2015	Wet Lab "Trabeculectomy"	2Hrs	Lecturer
3/2016	OKAP Review Lectures	4 Hrs	Lecturer
3/2016	Journal Club Glaucoma	2Hrs	Lecturer

**POSTGRADUATE MENTORSHIP:**

2015-2016	Benjamin Xu, MD, PhD	PGY4 2016	Career Guidance
2014-2015	Yohko Murakami, MD	PGY4 2015	Career Guidance

**SERVICE****DEPARTMENT SERVICE:**

2014-current	Compliance Committee	USC Eye Institute
12/2015-current	Residency Selection	USC Eye Institute
07/2014-current	Glaucoma Fellowship Selection	USC Eye Institute
07/2014-current	Postgraduate Education Committee	USC Eye Institute

**PROFESSIONAL SOCIETY MEMBERSHIPS:**

2010-current American Academy of Ophthalmology  
2013-current American Glaucoma Society  
2010-current Women In Ophthalmology  
2010-current American Society of Cataract and Refractive Surgeons

**RESEARCH AND SCHOLARSHIP****EDITORSHIPS AND EDITORIAL BOARDS:**

03/2015-current Editor Elsevier Editorial System

**MAJOR AREAS OF RESEARCH INTEREST**

## Research Areas

1. Minimally Invasive Glaucoma Surgery
2. Novel Surgical Techniques in Glaucoma

**PUBLICATIONS:****REFEREED JOURNAL ARTICLES:**

**Klimava, A, Akpek, E.** Evaluation of Patients with Dry Eye Syndrome for Associated Medical Conditions. ARVO 2007. Lecture presentation, May 2007. Published in *Cornea* September 2010;29(9):1072.  
**Reznik J, Salz, J, Klimava A.** Late Unilateral Corneal Ectasia After PRK With Preoperative Topography Suggestive of FFK. AAO Refractive Subspecialty Day, November 2006. Lecture presentation; Published in *J Refract Surg.* 2008 Oct;24(8):843-7.  
**Nagai N, Klimava A, Wen-Hsiang L, Handa J.** CTGF is increased in Basal Deposits and Regulates Matrix Production through the ERK (p42/p44<sup>mapk</sup>) MAPK and the p38<sup>mapk</sup> signaling pathways. Published in *Invest Ophthalmol Vis Sci.* 2009 Apr;50(4):1903-10.

**REFEREED JOURNAL ARTICLES IN PRESS:**

Format: Authors, Title. *Journal*. Volume #(Suppl ##):Page-Page, Year. PMID#, PMCID#, Narrative describing personal contribution.

**REFEREED REVIEWS, CHAPTERS, AND EDITORIALS:**

**Reznik, A, Varma, R.** (12/2015). Ab-Interno Subconjunctival Glaucoma Implant for Advanced Open-Angle Glaucoma

**CLINICAL COMMUNICATION: (CASE REPORTS, LETTERS)**

Authors. Title. *Journal* Volume(Suppl ##):Page-Page, Year. PMID#, PMCID#

**ON-LINE PUBLICATIONS:**

**Reznik A, Mukundum G, Sonu R, Lin L.** Imaging in immunohistologically proven orbital tumors. Submitted for a publication in *Radiographics*, May 2012

**BOOKS, MONOGRAPHS, AND TEXT BOOKS:**

Authors. Title. *Publication* Volume(Suppl ##):Page-Page, Year.

**LETTERS TO THE EDITOR:**

Authors. Title. *Publication* Volume(Suppl ##):Page-Page, Year. PMID#, PMCID#

**ABSTRACTS AND PRESENTATIONS:**

**Reznik A, Keltner J.** Emergency department direct ophthalmoscopy and non-mydratic funduscopy camera as a training tool. UC Davis research Symposium 2012. Lecture presentation.

**Reznik A**, Weber C, Telander D, Morse L, Thirkill C. Inflammatory reactions complicating exudative age-related macular degeneration. ARVO 2012. Poster presentation.

Akpek E, **Klimava A**, Thorne J, Martin D, Lekhanont K, Ostrovsky A. Evaluation of Dry Eye Patients for Presence of Underlying Sjogren's Syndrome. AAO 2007 meeting. Lecture presentation.

Gupta A, Sadeghi P, **Klimava A**, Akpek E. Occult thyroid eye disease in patients presenting with dry eye symptoms. Tear Film and Ocular Surface Society Annual Meeting, Taormina, Sicily, September 2007. Lecture presentation.

Reznik J, Salz, J, **Klimava A**. Late Unilateral Corneal Ectasia After PRK With Preoperative Topography Suggestive of FFK. AAO Refractive Subspecialty Day, November 2006. Lecture presentation; Published in J Refract Surg. 2008 Oct;24(8):843-7.

**Klimava A**, Handa J. Increased Connective Tissue Growth Factor in Basal Deposits of Bruch's Membrane of Human Maculae. American Geriatric Society Annual Meeting, May, 2007. Poster presentation.

**Klimava A**, Handa J. Connective Tissue Growth Factor Expression in ARMD. Johns Hopkins Summer Activities Symposium, October 2006. Poster presentation.

Reznik J, Kim A, **Klimava A**, Akpek E, Gatifloxacin 0.3% in treatment of bacterial keratitis; ARVO 2009. Poster presentation.